TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29868915
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg of pure (‐)‐epicatechin
Study: 21944980
Drug: End-range mobilization/scapular
Approvals — FDA: no, EMA: no, PMDA: no
Description: End-range mobilization/scapular mobilization treatment approach (EMSMTA)
Study: 21944980
Drug: Standardized physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized physical therapy program (criteria-control group)
Study: 15820454
Drug: Oral linezolid
Normalized name: Linezolid
DrugBank: Linezolid (DB00601)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral linezolid
Study: 10594478
Drug: Dipyridamole (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyridamole (200 mg) plus Acetylsalicylic Acid (25 mg)
Study: 1978472
Drug: Remoxipride (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remoxipride (mean daily dose 437 mg)
Study: 1978472
Drug: Haloperidol (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (mean daily dose 10.6 mg)
Study: 104084
Drug: Trifluorothymidine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trifluorothymidine (5 drops daily)
Study: 31915048
Drug: 1 week
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 week of antibiotic therapy for residual osteomyelitis
Study: 31915048
Drug: 3 weeks
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 weeks of antibiotic therapy for residual osteomyelitis
Study: 31915048
Drug: 1 day
Normalized name: ZonaCort 11 Day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 day of antibiotic therapy for remaining soft tissue infection
Study: 31915048
Drug: 4 days
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 days of antibiotic therapy for remaining soft tissue infection
Study: 31915048
Drug: 10 days
Normalized name: AlleRx 10-day Dose Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 days of antibiotic therapy for soft tissue infections
Study: 31915048
Drug: 20 days
Normalized name: ferrous fumarate
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 days of antibiotic therapy for soft tissue infections
Study: 31915048
Drug: 3 weeks
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 weeks of antibiotic therapy for osteomyelitis
Study: 31915048
Drug: 6 weeks
Normalized name: perampanel
DrugBank: Perampanel (DB08883)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 6 weeks of antibiotic therapy for osteomyelitis
Study: 22204724
Drug: Bevacizumab initiation
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab initiation (chemotherapy with bevacizumab added in cycles 2 through 6 and placebo in cycles 7 through 22)
Study: 22204724
Drug: Bevacizumab throughout
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab throughout (chemotherapy with bevacizumab added in cycles 2 through 22)
Study: 22204724
Drug: Control (chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (chemotherapy with placebo added in cycles 2 through 22)
Study: 22204724
Drug: Control (chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (chemotherapy with placebo)
Study: 19367154
Drug: HSV suppressive
Normalized name: Buckley's Cough Suppressant
Approvals — FDA: no, EMA: no, PMDA: no
Description: HSV suppressive therapy for 4-6 years
Study: 18593294
Drug: HSV suppressive
Normalized name: Buckley's Cough Suppressant
Approvals — FDA: no, EMA: no, PMDA: no
Description: HSV suppressive therapy
Study: 17323789
Drug: Fingolimod 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fingolimod 1.25 mg single dose
Study: 17323789
Drug: Fingolimod 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fingolimod 2.5 mg single dose
Study: 17323789
Drug: Fingolimod 5
Normalized name: fingolimod 500 MCG Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fingolimod 5 mg single dose
Study: 17323789
Drug: Fingolimod 5
Normalized name: fingolimod 500 MCG Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fingolimod 5 mg/day for 7 days
Study: 17323789
Drug: Fingolimod multiple-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fingolimod multiple-dose administration
Study: 17323789
Drug: Fingolimod single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fingolimod single and multiple doses
Study: 17323789
Drug: Fingolimod 5
Normalized name: fingolimod 500 MCG Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fingolimod 5 mg/day multiple dose
Study: 3198303
Drug: Atenolol plus
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atenolol plus nifedipine (10 mg t.i.d.)
Study: 477047
Drug: 0.125 mg
Normalized name: digoxin 0.125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.125 mg 3H‐digoxin intravenously and 0.125 mg orally as an alcoholic solution
Study: 477047
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg unlabelled digoxin intravenously or a digoxin tablet
Study: 30717153
Drug: DW2009 (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: DW2009 (800 mg/day)
Study: 30717153
Drug: Placebo (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (800 mg/day)
Study: 25961136
Drug: Daily TPTD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily TPTD for 24 months
Study: 25961136
Drug: Daily TPTD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily TPTD for 24 months in ALN-Rx women
Study: 22613418
Drug: 0.9% normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% normal saline infusion during spinal surgery (group SN)
Study: 19906909
Drug: 3.5 microg
Normalized name: neomycin sulfate 3.5 MICROGRAM In 1 GRAM / polymyxin B sulfate 10000 UNITS In 1 GRAM / bacitracin zinc 400 UNITS In 1 GRAM OPHTHALMIC OINTMENT [Neosporin]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.5 microg of the H5N1 vaccine (one or two doses)
Study: 19906909
Drug: 6 microg
Normalized name: Zotarolimus 1.6 microgram/mm2 drug eluting stent
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 microg of the H5N1 vaccine (single dose)
Study: 19906909
Drug: 12 microg
Normalized name: Levothyroxine sodium 112 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 microg of the H5N1 vaccine (single dose)
Study: 19906909
Drug: 3.5 microg
Normalized name: neomycin sulfate 3.5 MICROGRAM In 1 GRAM / polymyxin B sulfate 10000 UNITS In 1 GRAM / bacitracin zinc 400 UNITS In 1 GRAM OPHTHALMIC OINTMENT [Neosporin]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.5 microg of the H5N1 vaccine (one injection)
Study: 19906909
Drug: 3.5 microg
Normalized name: neomycin sulfate 3.5 MICROGRAM In 1 GRAM / polymyxin B sulfate 10000 UNITS In 1 GRAM / bacitracin zinc 400 UNITS In 1 GRAM OPHTHALMIC OINTMENT [Neosporin]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.5 microg of the H5N1 vaccine
Study: 17914516
Drug: Topical mitomycin
Normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical mitomycin C (MMC) 0.4 mg/mL for 4 minutes
Study: 16275598
Drug: All three
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: All three drugs (Desipramine, Amitriptyline, Fluoxetine)
Study: 11861354
Drug: inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: inhaled nitric oxide (iNO) 10 ppm in 100% oxygen
Study: 535856
Drug: Oral contraceptives
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptives (specific types not mentioned)
Study: 535856
Drug: Two oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two oral contraceptives (different in dosage)
Study: 23988507
Drug: High-dose-rate (HDR)
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose-rate (HDR) brachytherapy (BT) boost after external beam irradiation (mean dose 62 Gy, range 50-70 Gy)
Study: 16340517
Drug: Free nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Free nicotine replacement therapy (NRT) voucher
Study: 11403336
Drug: Hydroxychloroquine 200
Normalized name: hydroxychloroquine 200 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxychloroquine 200 mg twice daily for 11 weeks
Study: 11403336
Drug: Hydroxychloroquine 200
Normalized name: hydroxychloroquine 200 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxychloroquine 200 mg twice daily plus colchicine 0.6 mg twice daily for 12 weeks
Study: 3312552
Drug: Indomethacin (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (0.2 mg/kg intravenously, 24 hours after birth)
Study: 27015752
Drug: Biological fixation
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological fixation (indirect reduction)
Study: 23579888
Drug: hemostatic agent‐contaminated
Approvals — FDA: no, EMA: no, PMDA: no
Description: hemostatic agent‐contaminated and rinsing with water
Study: 23579888
Drug: hemostatic agent‐contaminated
Approvals — FDA: no, EMA: no, PMDA: no
Description: hemostatic agent‐contaminated and ethylene diamine tetraacetic acid (EDTA) application
Study: 23579888
Drug: hemostatic agent‐contaminated
Approvals — FDA: no, EMA: no, PMDA: no
Description: hemostatic agent‐contaminated and phosphoric acid application
Study: 20826420
Drug: Kinesiotaping combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kinesiotaping combined with botulinum toxin A (BTX‐A) injection
Study: 20826420
Drug: Sham-taping combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham-taping combined with botulinum toxin A (BTX‐A) injection
Study: 7723357
Drug: Isomazole 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isomazole 5 mg
Study: 7723357
Drug: Isomazole 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isomazole 10 mg
Study: 7723357
Drug: Isomazole 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isomazole 20 mg
Study: 7723357
Drug: Isomazole 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isomazole 30 mg
Study: 7723357
Drug: Isomazole (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isomazole (all doses)
Study: 26666319
Drug: Prednisolone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (1 mg/kg per day)
Study: 31276165
Drug: Pre-antibiotic microbiota
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-antibiotic microbiota profiles
Study: 27559855
Drug: Ginger group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginger group (GG) - 500 mg ginger powder daily for 3 months
Study: 27559855
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group (PG) - 500 mg starch daily for 3 months
Study: 24709512
Drug: DBM with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: DBM with rhBMP-2 (0.05 mg/mL)
Study: 12841551
Drug: Infiltration with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infiltration with 80 ml of 0.125 % Bupivacaine containing 5 mg of Phenylephrine (G2)
Study: 12841551
Drug: Infiltration with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infiltration with 80 ml of 0.9 % NaCl (G3)
Study: 12841551
Drug: Infiltration with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infiltration with Bupivacaine/Phenylephrine and 200 ml of normal saline containing 0.15 % of Lidocaine (G4)
Study: 8877075
Drug: Lisinopril, 20
Normalized name: Lisinopril, 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril, 20 mg/day by mouth
Study: 31146701
Drug: Prediction score
Normalized name: fecal microbiota spores, live Oral Capsule [Vowst]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prediction score for acute kidney injury (AKI) based on risk factors including hypertension history, heart rate > 100 bpm on admission, peak serum troponin I ≥ 100 μg/L, time from admission to coronary reperfusion > 120 min, Killip classification ≥ class 3 on admission, maximum dosage of intravenous furosemide ≥ 60 mg/d, shock during hospitalization, and baseline estimated glomerular filtration rate (eGFR) < 90 ml/min·1.73 m2.
Study: 26251312
Drug: OTC medication
Normalized name: Medicated Shampoo
Approvals — FDA: no, EMA: no, PMDA: no
Description: OTC medication (containing cetylpyridinium chloride, dipotassium glycyrrhizate, and allantoin) applied twice a day for 12 weeks
Study: 26251312
Drug: OTC medication
Normalized name: Medicated Shampoo
Approvals — FDA: no, EMA: no, PMDA: no
Description: OTC medication
Study: 24521036
Drug: Desires for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desires for Drug Questionnaire (DDQ) desire and intention scores
Study: 24521036
Drug: Desires for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desires for Drug Questionnaire (DDQ) negative reinforcement scores
Study: 24521036
Drug: Desires for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desires for Drug Questionnaire (DDQ) control scores
Study: 7577277
Drug: Continuous paravertebral
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous paravertebral infusion of bupivacaine
Study: 22100213
Drug: Incentive spirometry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incentive spirometry in epidural bupivacaine alone and continuous paravertebral infusion of bupivacaine
Study: 12099976
Drug: Rosiglitazone (RSG)
DrugBank: Rosiglitazone (DB00412)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rosiglitazone (RSG) 4 mg/day
Study: 28668243
Drug: Misoprostol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol (200 μg) administered at 30 minutes, 90 minutes, and 4 hours after the first dose of nasal ketorolac
Study: 29428183
Drug: Mass azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mass azithromycin treatment
Study: 19661847
Drug: Bacteriophage treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacteriophage treatment
Study: 14602361
Drug: Placebo level
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo level of alcohol (0.04 g/kg)
Study: 14602361
Drug: Moderate dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate dose of alcohol (0.40 g/kg)
Study: 14602361
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose of alcohol (0.80 g/kg)
Study: 10717252
Drug: Certoparin (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Certoparin (low molecular weight heparin)
Study: 10717252
Drug: UF heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: UF heparin (unfractionated heparin)
Study: 1400008
Drug: Protein supplementation
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein supplementation (PROIN) at 2.62 g.kg‐1.day‐1
Study: 1400008
Drug: Carbohydrate supplementation
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate supplementation (CHO) at 1.35 g.kg‐1.day‐1
Study: 31642725
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (exercise therapy + abdominal binding)
Study: 26460695
Drug: Sinovac Enterovirus
Normalized name: human enterovirus A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sinovac Enterovirus 71 vaccine
Study: 24879494
Drug: 100,000 units
Normalized name: nystatin 100,000 units vaginal tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100,000 units oral vitamin D3 every 3 months for 1 year
Study: 17568152
Drug: Hydrocortisone (HC)
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone (HC) 0.5 mg/kg/12 h for 9 days, then HC 0.5 mg/kg/24 h for 3 days
Study: 16280447
Drug: Calcium (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium (1000 mg) + Vitamin D3 (200 IU)
Study: 22112804
Drug: Calcium (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium (1000 mg)
Study: 16280447
Drug: Cheese (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cheese (1000 mg calcium)
Study: 12123334
Drug: Accelerated infusional
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated infusional ECF with G-CSF support
Study: 9691864
Drug: 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline 1000 ml i.v. over a 30‐min period
Study: 9691864
Drug: Hydroxyethyl starch
Normalized name: Hydroxyethyl starch
DrugBank: Hydroxyethyl Starch (DB09106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyethyl starch (200/0.5) 1000 ml i.v. over a 30‐min period
Study: 29231344
Drug: Drug oil
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug oil moxibustion
Study: 29231344
Drug: Western medication
Normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medication (tamsulosin hydrochloride)
Study: 20595146
Drug: SiNQ-5 questionnaire
Approvals — FDA: no, EMA: no, PMDA: no
Description: SiNQ-5 questionnaire (self-administered, scoring 0-10 points)
Study: 17217214
Drug: Placebo toothpaste
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo toothpaste (without any therapeutic agents)
Study: 10757545
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg DHA/d for 3 months
Study: 10757545
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg DHA/d for 3 months
Study: 10757545
Drug: Placebo (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0 mg DHA/d for 3 months)
Study: 8827810
Drug: Azelastine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azelastine administered orally twice a day
Study: 1424413
Drug: L-654,066 (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-654,066 (0.1 mg)
Study: 1424413
Drug: L-654,066 (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-654,066 (0.5 mg)
Study: 1424413
Drug: L-654,066 (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-654,066 (1 to 25 mg)
Study: 1424413
Drug: L-654,066 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-654,066 (50 to 100 mg)
Study: 19299087
Drug: Extended intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extended intervention (10 sessions motivational interviewing/cognitive-behavior therapy)
Study: 11420782
Drug: Cholecalciferol treatment
Normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol treatment (800 IU daily)
Study: 2785813
Drug: Diclofenac (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac (50 mg)
Study: 27287612
Drug: Standard artemether-lumefantrine
Normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard artemether-lumefantrine (AL) regimen + 0.25 mg/kg single-dose of primaquine (PQ)
Study: 22100962
Drug: Discussions about
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discussions about burden of treatment (BOT) during clinical visits
Study: 22100962
Drug: Discussions about
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discussions about monitoring, treatment administration, access, and treatment effects
Study: 22100962
Drug: Addressing burden
Normalized name: DRESSING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Addressing burden of treatment (BOT)
Study: 19397539
Drug: 15% glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15% glucose infusion
Study: 19702752
Drug: Levetiracetam (20-60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levetiracetam (20-60 mg/kg/day)
Study: 12875347
Drug: Lisinopril/hydrochlorothiazide (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril/hydrochlorothiazide (20 mg/12.5 mg)
Study: 1878244
Drug: 0.1% dimetindene
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% dimetindene gel
Study: 30508141
Drug: cCBT (computerized
Approvals — FDA: no, EMA: no, PMDA: no
Description: cCBT (computerized cognitive behavioral therapy) intervention, Beating the Blues, with care coach support for eight sessions
Study: 30508141
Drug: cCBT (computerized
Approvals — FDA: no, EMA: no, PMDA: no
Description: cCBT (computerized cognitive behavioral therapy) intervention
Study: 23212677
Drug: Structured intervention
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured intervention consisting of psychoeducation and cognitive behavioral therapy (6 one-hour sessions with a psychologist)
Study: 19477443
Drug: Intraperitoneal instillation
Normalized name: Taurolidine 20 mg/mL solution for intraperitoneal instillation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal instillation of 120 mg of lidocaine
Study: 13678227
Drug: 1% Fennel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% Fennel extract cream
Study: 13678227
Drug: 2% Fennel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% Fennel extract cream
Study: 13678227
Drug: Placebo (0%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0% Fennel extract cream)
Study: 9192125
Drug: Random urine
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Random urine testing for performance enhancing drugs (anabolic steroids, diuretics, caffeine, peptide hormones, pseudoephedrine, probenecid, methoxyphenamine, dextropropoxyphene)
Study: 1300947
Drug: Topical antibiotics
Normalized name: Tetracycline and derivatives, topical antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical antibiotics (latamoxef, cefmenoxime, cefotiam, cefamandole) administered during operation at a dose of 1 or 2 g
Study: 1300947
Drug: Systemic antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic antibiotics (cefem antibiotics) administered by intravenous drip at a dose of 1 or 2 g, twice daily for 4 to 7 days postoperatively
Study: 22949162
Drug: Segmental neuromyotherapy
Normalized name: casein, emmental cultured
Approvals — FDA: no, EMA: no, PMDA: no
Description: Segmental neuromyotherapy combined with standard therapy
Study: 20974574
Drug: Miconazole buccal
Normalized name: miconazole Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Miconazole buccal tablet (MBT) 50 mg once daily
Study: 20974574
Drug: Clotrimazole troches
Normalized name: clotrimazole
DrugBank: Clotrimazole (DB00257)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clotrimazole troches (CT) 10 mg 5 times daily
Study: 7324992
Drug: Flupenthixol decanoate
Normalized name: flupenthixol decanoate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flupenthixol decanoate (20 mg every 2-3 weeks)
Study: 22294641
Drug: Sodium oxybate
Normalized name: Sodium Oxybate
DrugBank: Sodium oxybate (DB09072)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium oxybate 4.5 g/night
Study: 22294641
Drug: Sodium oxybate
Normalized name: Sodium Oxybate
DrugBank: Sodium oxybate (DB09072)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium oxybate 6 g/night